The example of crizotinib, an FDA-approved tyrosine kinase inhibitor for the treatment of EML4-ALK–rearranged NSCLC, shows that proteins encoded by fusion transcripts can also be harnessed as innovative drug targets [9]. Here, ALK is linked to non-small cell lung carcinoma.